A Randomized, Placebo-Controlled Trial of Certolizumab Pegol (CDP870) for Treatment of Crohn’s Disease-Reference-Cited by-同舟云学术

A Randomized, Placebo-Controlled Trial of Certolizumab Pegol (CDP870) for Treatment of Crohn’s Disease

Published:2005-09 Issue:3 Volume:129 Page:807-818
ISSN:0016-5085
Container-title:Gastroenterology
language:en
Short-container-title:Gastroenterology

Author:

Schreiber Stefan,Rutgeerts Paul,Fedorak Richard N.,Khaliq–Kareemi Munaa,Kamm Michael A.,Boivin Michel,Bernstein Charles N.,Staun Michael,Thomsen Ole Østergaard,Innes Alison

Publisher

Elsevier BV

Subject

Gastroenterology,Hepatology

Reference34 articles.

1. Serum concentrations of tumour necrosis factor alpha in childhood chronic inflammatory bowel disease;Murch;Gut,1991

2. Localisation of tumour necrosis factor alpha by immunohistochemistry in chronic inflammatory bowel disease;Murch;Gut,1993

3. Tumour necrosis factor alpha in stool as a marker of intestinal inflammation;Braegger;Lancet,1992

4. Enhanced secretion of tumour necrosis factor-alpha, IL-6, and IL-1 beta by isolated lamina propria mononuclear cells from patients with ulcerative colitis and Crohn’s disease;Reinecker;Clin Exp Immunol,1993

5. Tumour necrosis factor and Crohn’s disease;van Deventer;Gut,1997

Cited by 513 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Aktualisierte S3-Leitlinie „Diagnostik und Therapie des Morbus Crohn“ der Deutschen Gesellschaft für Gastroenterologie, Verdauungs- und Stoffwechselkrankheiten (DGVS) (Version 4.1) – living guideline;Zeitschrift für Gastroenterologie;2024-08

2. ECCO Guidelines on Therapeutics in Crohn’s Disease: Medical Treatment;Journal of Crohn's and Colitis;2024-06-15

3. Network meta‐analysis: Comparative onset of early effect of biologics and small molecules in moderately to severely active luminal Crohn's disease;Alimentary Pharmacology & Therapeutics;2024-06-11

4. Comparison of efficacy discrepancy between early-phase clinical trials and phase III trials of PD-1/PD-L1 inhibitors;Journal for ImmunoTherapy of Cancer;2024-01

5. Anti-Tumour Necrosis Factor and New Paradigms for Therapies Using Antibodies;Molecular Biology of B Cells;2024